BioSpace News Archive

BioInvent International invites investors, analysts and the press to a presentation of the interim report January- September 2023 at 2:00 pm on Thursday October 26. The report will be published at 8:00 am CET the same day. BioInvent’s CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When:

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the market.

Vericel Corporation today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023.

Hepion Pharmaceuticals, Inc. announced the publication of a new research study in mice, where Hepion’s lead drug candidate, rencofilstat, prevented the growth of liver tumors that occurred as a result of chronic infection with the human hepatitis C virus (“HCV”).

Enterome today announces that Pierre Bélichard, CEO, will present an overview of the Company and participate in 1-on-1 meetings with institutional investors at the following investor meetings.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, is pleased to announce its participation, in-person, at the Jefferies London Healthcare Conference and at McDermott Will & Emery’s Life Sciences Symposium.

ANGLE plc is pleased to announce the publication of a study using the Parsortix system that sheds new light on the phenotypic characteristics of CTCs in Head and Neck Squamous Cell Carcinoma.

Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company’s clinical phase 2 study in patients with retinal vein occlusion with the investigational drug candidate ANXV.

MorphoSys AG reported preliminary Monjuvi® U.S. Net Product Sales and Gross Margin for the third quarter of 2023 and provided an update to its financial guidance for 2023.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, reported financial results for the third quarter ending September 30, 2023.